Showing 1 - 5 results of 5 for search 'E Eleutherakis-Papaiakovou', query time: 0.02s Refine Results
  1. 1
    P54 ORAL ANTIVIRALS RITONAVIR-NIRMATRELVIR AND MOLNUPIRAVIR ARE HIGHLY EFFECTIVE IN PATIENTS WITH MULTIPLE MYELOMA AND COVID-19; A SINGLE-CENTER, PROSPECTIVE STUDY

    P54 ORAL ANTIVIRALS RITONAVIR-NIRMATRELVIR AND MOLNUPIRAVIR ARE HIGHLY EFFECTIVE IN PATIENTS WITH MULTIPLE MYELOMA AND COVID-19; A SINGLE-CENTER, PROSPECTIVE STUDY by V. Spiliopoulou, I. Ntanasis-Stathopoulos, P. Malandrakis, M. Gavriatopoulou, F. Theodorakakou, D. Fotiou, R. E. Syrigou, M. Migkou, M. Roussou, E. Eleutherakis-Papaiakovou, E. Kastritis, M. A Dimopoulos, E. Terpos

    Published 2023-05-01
    Get full text
    Article
  2. 2
    P57 PRE-EXPOSURE PROPHYLAXIS FOR COVID-19 WITH TIXAGEVIMAB/CILGAVIMAB (EVUSHELD) IN PATIENTS WITH MULTIPLE MYELOMA

    P57 PRE-EXPOSURE PROPHYLAXIS FOR COVID-19 WITH TIXAGEVIMAB/CILGAVIMAB (EVUSHELD) IN PATIENTS WITH MULTIPLE MYELOMA by I. Ntanasis-Stathopoulos, M. Gavriatopoulou, E. Eleutherakis-Papaiakovou, P. Malandrakis, V. Spiliopoulou, R.E. Syrigou, F. Theodorakakou, D. Fotiou, M. Migkou, M. Roussou, E. Kastritis, M.A. Dimopoulos, E. Terpos

    Published 2023-05-01
    Get full text
    Article
  3. 3
    P14 OCULAR TOXICITY IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH BELANTAMAB MAFODOTIN, LENALIDOMIDE AND DEXAMETHASONE IN A PHASE 1/2 TRIAL

    P14 OCULAR TOXICITY IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH BELANTAMAB MAFODOTIN, LENALIDOMIDE AND DEXAMETHASONE IN A PHASE 1/2 TRIAL by I. Ntanasis-Stathopoulos, M. Gavriatopoulou, P. Malandrakis, D. Fotiou, N. Kanellias, M. Migkou, F. Theodorakakou, V. Spiliopoulou, R. Syrigou, E. Eleutherakis-Papaiakovou, S. Gkolfinopoulos, K. Manousou, E. Kastritis, M.A. Dimopoulos, E. Terpos

    Published 2023-05-01
    Get full text
    Article
  4. 4
    P16: DARATUMUMAB MONOTHERAPY HAS A FAVORABLE EFFECT ON BONE METABOLISM IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA; RESULTS OF THE PHASE 2 REBUILD STUDY

    P16: DARATUMUMAB MONOTHERAPY HAS A FAVORABLE EFFECT ON BONE METABOLISM IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA; RESULTS OF THE PHASE 2 REBUILD STUDY by E Terpos, I Ntanasis-Stathopoulos, E Kastritis, E Hatjiharissi, E Katodritou, E Eleutherakis-Papaiakovou, E Verrou, M Gavriatopoulou, A Leonidakis, S Delimpasi, P Malandrakis, M-C Kyrtsonis, M Papaioannou, A Symeonidis, MA Dimopoulos

    Published 2022-04-01
    Get full text
    Article
  5. 5
    B06 HIGH LEVELS OF CIRCULATING PLASMA CELLS AT DIAGNOSIS ARE PREDICTIVE FOR WORSE PROGNOSIS IN BOTH TRANSPLANT-ELIGIBLE AND -INELIGIBLE PATIENTS WITH MULTIPLE MYELOMA

    B06 HIGH LEVELS OF CIRCULATING PLASMA CELLS AT DIAGNOSIS ARE PREDICTIVE FOR WORSE PROGNOSIS IN BOTH TRANSPLANT-ELIGIBLE AND -INELIGIBLE PATIENTS WITH MULTIPLE MYELOMA by P. Malandrakis, I. Ntanasis-Stathopoulos, I.V. Kostopoulos, P. Roussakis, E. Eleutherakis-Papaiakovou, C. Panteli, N. Angelis, V. Spiliopoulou, N. Orologas-Stavrou, F. Theodorakakou, D. Fotiou, M. Migkou, M. Gavriatopoulou, E. Kastritis, O.E. Tsitsilonis, M.A. Dimopoulos, E. Terpos

    Published 2023-05-01
    Get full text
    Article

Search Tools: